On Monday, Shares of Facebook, Inc. (NASDAQ:FB), gained 1.39% to $80.29, after the company rolled out a new layer of security to protect its users-encrypted notification emails.
“It’s very important to us that the people who use Facebook feel safe and can trust that their connection to Facebook is secure,” the company said in its blog post.
Facebook, Inc. operates as a social networking company worldwide. It provides a set of development tools and application programming interfaces that enable developers to integrate with Facebook to create mobile and Web applications.
Shares of SINA Corporation (NASDAQ:SINA), surged 23.28% to $50.21, during its last trading session.
SINA Corporation, declared that it has reached a legally binding subscription agreement with Mr. Charles Chao, Chairman of SINA’s board of directors and Chief Executive Officer, for the issuance and sale of 11,000,000 newly issued ordinary shares of the Company to Mr. Chao. Following the agreement, Mr. Chao will subscribe for and purchase directly or through a special purpose vehicle beneficially owned and controlled by him, 11,000,000 newly issued ordinary shares of SINA for a total purchase price of about US$456 million in cash. The per share purchase price of US$41.49 represents the average closing trading price of SINA’s ordinary shares for the 30 trading days ended May 29, 2015 and is higher than the closing trading price on May 29, 2015, the last trading day before the signing of the subscription agreement. Mr. Chao has agreed to subject all the shares he or his associate will acquire in the transaction to a contractual lock-up restriction for six months after the closing. The closing is predictable to take place upon satisfaction of customary closing conditions.
SINA Corporation, through its auxiliaries, operates as an online media company in the People’s Republic of China. It operates SINA.com, an online brand advertising portal that provides region-focused format and content, counting multimedia news; sporting events news; automobile-related news; business news coverage and personal finance columns; entertainment news and events; technology updates; interactive video products, such as news, sports, entertainment, and education; and education, digital, fashion, eLadies, luxury, health, collectibles, travel, and other interest-based channels.
At the end of Monday’s trade, Shares of NetApp, Inc. (NASDAQ:NTAP), lost -0.73% to $33.15.
NetApp, declared changes to the executive leadership team and board of directors, effective right away. George Kurian has been designated by the board as chief executive officer and also designated to the board of directors. Lead independent director Mike Nevens has been elected chairman of the board. These declarations follow the departure of Tom Georgens, the company’s former chairman and chief executive officer.
Mr. Kurian joined NetApp in 2011 and has served as the company’s executive vice president, Product Operations where he was responsible for overseeing the strategy and development of NetApp’s Product and Solutions portfolio since September 2013.
NetApp, Inc. is engaged in design, manufacture, and marketing of networked storage solutions. The company provides storage and data administration software, systems, and services.
Finally, OXiGENE, Inc. (NASDAQ:OXGN), ended its last trade with 6.25% gain, and closed at $1.53.
OXiGENE, offered an update on recent discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a projected Phase 3 trial of fosbretabulin in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
- FDA agreed with the company’s proposal to test the combination anti-vascular regimen of fosbretabulin and bevacizumab directly against chemotherapy using progression-free survival (PFS) as the primary endpoint in a randomized, controlled registration trial.
- FDA requested inclusion of a third arm, of bevacizumab alone, in the trial to further characterize the efficacy of each individual drug in the combination.
- OXiGENE intends to submit an application to the FDA for a Special Protocol Assessment (SPA) later this year.
OXiGENE, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents to treat cancer in the United States. Its principal clinical stage product comprises fosbretabulin tromethamine, a reversible tubulin binding agent, which has accomplished Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating gastrointestinal neuroendocrine tumors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
